Kimberly-Clark Corp.
Kimberly-Clark Corporation (KMB)
Overview
Kimberly-Clark Corporation is a global consumer products company focused on personal care and hygiene, headquartered in Irving, Texas. Founded in 1872 in Neenah, Wisconsin, as a paper manufacturer, the company built its modern identity around iconic brands such as Huggies, Kleenex, Kotex, Scott, Cottonelle, Poise, and Depend. Kimberly-Clark moved its primary listing from the NYSE to the Nasdaq in May 2025. It reported roughly $16.4 billion in revenue for fiscal 2025 (down sharply from about $20 billion in 2024, reflecting the deconsolidation of its global tissue business into a joint venture) and employs around 36,000–38,000 people worldwide. The company is a Fortune 500 mainstay and one of the world's largest makers of paper-based and personal-care consumer products, competing globally against Procter & Gamble, Essity, Unicharm, and other household-products manufacturers.
What They Do & How They Make Money
Kimberly-Clark designs, manufactures, and markets branded, largely disposable personal-care and hygiene products that it sells primarily through mass retailers, grocery and drug chains, e-commerce, and — for its professional lines — business-to-business distributors. Revenue is generated the classic consumer-packaged-goods way: the company manufactures products at large-scale global plants, builds brand equity through advertising and innovation (softer diapers, better absorbency, new formats), and sells them at a markup through retail partners such as Walmart, Costco, Target, and Amazon, as well as directly to consumers online. A meaningful share of revenue also comes from away-from-home and professional channels — washroom, wiping, and safety products sold to businesses, schools, and institutions under brands like WypAll and Kleenex Professional. The company's profitability depends heavily on input costs (pulp, oil-based resins, and other raw materials), manufacturing efficiency, pricing power against private-label competition, and its ability to keep innovating in categories like diapers and feminine/adult care where brand loyalty and product performance matter more than in commodity paper goods. In 2025, Kimberly-Clark restructured its global tissue operations into Arbex, a roughly $3.4 billion joint venture with Brazilian pulp producer Suzano that became operational in mid-2026; Arbex now runs 22 manufacturing sites across 14 countries and licenses the Kleenex and Scott names, allowing Kimberly-Clark to concentrate its owned, consolidated business more tightly on personal care. Separately, in November 2025 Kimberly-Clark announced a roughly $48.7 billion agreement to acquire Kenvue (the former Johnson & Johnson consumer-health spinoff whose brands include Tylenol, Band-Aid, Listerine, Aveeno, and Neutrogena), a deal expected to close by year-end 2026 that would substantially expand the company into consumer health and skin/personal care beyond its traditional hygiene base.
Business Segments
Following the tissue joint venture, Kimberly-Clark now reports primarily through two operating segments:
- North America Personal Care — The company's largest and most profitable segment, covering baby and child care (Huggies diapers, Pull-Ups and Goodnites training pants), feminine care (Kotex), and adult incontinence care (Poise, Depend) sold across the US and Canada. This segment also historically included North American consumer tissue products (Kleenex, Scott, Cottonelle, Viva) prior to the Arbex transaction, and continues to house North American retail relationships and brand marketing for the core hygiene portfolio.
- International Personal Care (K-C International) — The equivalent personal-care business (baby care, feminine care, adult care) sold in Kimberly-Clark's international markets across Latin America, Asia-Pacific, Eastern Europe, the Middle East, and Africa, where Huggies in particular is a leading global diaper brand.
- K-C Professional (workplace/away-from-home) — Historically a distinct segment supplying wipers, safety products, washroom and hygiene solutions (WypAll, Kleenex Professional, Scott Professional) to businesses, industrial customers, and institutions; this line of business continues to be sold through commercial channels alongside the consumer segments.
Prior to the 2025 restructuring, Kimberly-Clark's tissue products (Kleenex facial tissue, Scott and Cottonelle bath tissue, Viva towels) were reported within North America Consumer Tissue and K-C International, contributing meaningfully to overall revenue; the Arbex joint venture removed the bulk of that tissue manufacturing and revenue from Kimberly-Clark's consolidated results starting in 2025–2026, which explains the roughly 18% revenue decline reported for fiscal 2025 versus 2024. Personal care — driven by North America — remains the largest profit contributor, given diapers' and feminine/adult-care products' stronger margins and brand loyalty relative to commodity tissue.
Competitors
- Global personal care and household products: Procter & Gamble (Pampers, Always, Charmin, Bounty) is Kimberly-Clark's largest and most direct global rival across diapers, feminine care, and tissue/paper towels.
- Tissue and hygiene (including through the new Arbex JV structure): Essity (Sweden), Georgia-Pacific (owned by Koch Industries, maker of Angel Soft and Brawny), WEPA, and now indirectly Suzano as Arbex's co-owner and pulp supplier.
- Baby and diaper care: Unicharm (Japan), Essity, and regional/private-label diaper makers, particularly in emerging markets where Huggies competes for share.
- Feminine and adult incontinence care: Procter & Gamble (Always, Tampax), Essity (TENA), and Edgewell Personal Care.
- Private label / store brands: Increasingly significant competitors across nearly every category (diapers, wipes, tissue) at mass retailers like Walmart, Costco, and Amazon, pressuring pricing in more commoditized segments.
- Pending consumer-health competitors (post-Kenvue deal): Should the Kenvue acquisition close, Kimberly-Clark would compete more directly with Johnson & Johnson, Bayer, Haleon, and Reckitt Benckiser in over-the-counter health, skin care, and oral care.
Competitive Position
Kimberly-Clark's core moat is brand strength in categories where consumers are reluctant to switch — parents trust Huggies for their baby's skin, and Kleenex has become a genericized trademark for facial tissue. Decades of R&D investment in absorbent-core technology, nonwoven materials, and manufacturing scale give it cost and quality advantages that are difficult for smaller or private-label competitors to match in performance-sensitive categories like diapers and adult incontinence care. Its 2025 strategic pivot — shedding tissue manufacturing into the Arbex joint venture while pursuing the large Kenvue acquisition — signals a deliberate shift toward higher-margin, brand-differentiated personal care and consumer health, away from capital-intensive, lower-margin commodity paper production. This should, if executed well, improve capital efficiency and margins, but it also concentrates the company's risk: integration of a target as large as Kenvue carries substantial execution, financing, and regulatory risk, and the deal was still pending as of the most recent reporting. Key risks include continued private-label encroachment in tissue and diapers, input-cost volatility (pulp, resin, and other petroleum-linked materials), foreign-exchange exposure given its large international footprint, category headwinds such as reported disruption to China diaper sales tied to social-media dynamics, and the general challenge mature consumer-staples companies face in generating organic volume growth in developed markets. Kimberly-Clark's dependence on a small number of very large retail customers (Walmart chief among them) for a significant share of sales also gives those retailers meaningful negotiating leverage over pricing and shelf space.